Search

everythinglearnresearchcommunity

for

Search:↓

SARS-CoV-2, the virus causing COVID-19, can affect all endocrine organs and systems, altering their function and potentially leading to disorders. Factors like diabetes and obesity increase infection risk and severity. Understanding these effects is key for effective treatment.

Androgen deprivation therapy might be better for preventing COVID-19 than treating it.

The drug enzalutamide may reduce the ability of the virus causing COVID-19 to enter lung cells.

The conclusion is that individual differences in COVID-19 severity are influenced by factors like age, sex, race, and genetics, which are important for personalized medicine.

Androgens may worsen COVID-19 and hair loss could indicate the disease's severity.

Blocking the virus's entry into cells by targeting certain pathways could lead to early COVID-19 treatments.

Certain genes and nutrients like vitamin D, zinc, and omega fatty acids affect COVID-19 severity and infection risk.

Anti-androgen therapy might help protect against COVID-19 infection and reduce death risk.

Proxalutamide significantly lowered hospitalization rates in women with mild-to-moderate COVID-19.

The ACE1 gene variant doesn't affect long-COVID symptoms.

Men with androgenetic alopecia and hypertension may experience more severe COVID-19.

Women with conditions like PCOS may have a higher risk of COVID-19, but treatments like isotretinoin could help those with acne.

Men are more likely to have severe COVID-19 cases and fatalities than women due to factors like lifestyle, aging, and biological differences.

After severe COVID-19, 71% of patients experienced excessive hair shedding and thinning within 3 months due to factors like low oxygen levels, medication, stress, and autoimmune disease.

COVID-19 may affect male fertility and women might have better outcomes due to hormonal and immune differences.

Anti-androgen therapy may boost immunity but increases injection site pain in vaccinated patients.

Hair loss doesn't affect COVID-19 severity.

Men, especially older ones with health issues like prostate cancer, may have worse COVID-19 outcomes and could benefit from therapies targeting male hormones.

5-alpha reductase inhibitors might worsen lung recovery in COVID-19 patients, suggesting a pause in their use.

Testosterone's effects on COVID-19 are unclear and need more research.

Androgen deprivation therapy doesn't lower the risk of death from COVID-19 in prostate cancer patients.

PrEP doesn't increase STI risk in high-risk men, anti-androgen drugs may lower ICU admission for male COVID-19 patients, a 3-point injection is better for crow's feet, and the 'Geriatric-8' tool could help assess frailty in older skin cancer patients.

The letter suggests testosterone replacement therapy might worsen COVID-19 outcomes.

COVID-19 may worsen with androgens; anti-androgen drugs could help.

Combining iron supplements with physiotherapy could better treat women's hair loss linked to iron deficiency.

COVID-19 might worsen symptoms and progression of benign prostatic hyperplasia, possibly due to inflammation and metabolic disturbances in the prostate gland. More research is needed to confirm this.

COVID-19 and hypopituitarism (reduced pituitary gland function) are linked, with the latter's related health issues potentially worsening COVID-19 outcomes, and COVID-19 possibly increasing risk for pituitary complications.

Some vitamins and minerals like vitamin D and iron can help with certain types of hair loss, but more research is needed for others.

Anabolic steroid users may face higher risk of severe COVID-19.

Proxalutamide significantly lowered hospital admissions for male COVID-19 patients compared to a placebo.